UB Paderborn / Katalog / Suche / in CDI

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Cell metabolism, 2017-10, Vol.26 (4), p.633-647.e7

2017

Link zum Volltext

Verfügbarkeit prüfen

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Nature communications, 2019-03, Vol.10 (1), p.1373-1373, Article 1373

2019

Link zum Volltext

Verfügbarkeit prüfen

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

Nature communications, 2020-10, Vol.11 (1), p.5488-15, Article 5488

2020

Link zum Volltext

Verfügbarkeit prüfen

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Cancer and metastasis reviews, 2016-12, Vol.35 (4), p.515-524

2016

Link zum Volltext

Verfügbarkeit prüfen

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-03, Vol.17 (3), p.367-377

2016

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Trials in ER + Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Cancer discovery, 2017-06, Vol.7 (6), p.561-574

2017

Link zum Volltext

Verfügbarkeit prüfen

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER + Breast Cancer

Clinical cancer research, 2017-10, Vol.23 (20), p.6138-6150

2017

Link zum Volltext

Verfügbarkeit prüfen

Trajectories of alcohol consumption during life and the risk of developing breast cancer

British journal of cancer, 2021-10, Vol.125 (8), p.1168-1176

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: Neoadjuvant Trials in ER + Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Cancer discovery, 2019-02, Vol.9 (2), p.304-304

2019

Link zum Volltext

Verfügbarkeit prüfen

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain

The oncologist (Dayton, Ohio), 2020-09, Vol.25 (9), p.e1339-e1345

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Scientific reports, 2021-02, Vol.11 (1), p.4433-11, Article 4433

2021

Link zum Volltext

Verfügbarkeit prüfen

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

Scientific reports, 2020-05, Vol.10 (1), p.7741-7741, Article 7741

2020

Link zum Volltext

Verfügbarkeit prüfen

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women

Cancer treatment reviews, 2013-08, Vol.39 (5), p.457-465

2013

Link zum Volltext

Verfügbarkeit prüfen

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER + Breast Cancer

Clinical cancer research, 2019-02, Vol.25 (4), p.1433-1433

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

Cancers, 2022-09, Vol.14 (19), p.4705

2022

Link zum Volltext

Verfügbarkeit prüfen

Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer

Cancer research communications, 2022-05, Vol.2 (5), p.286-292

2022

Link zum Volltext

Verfügbarkeit prüfen

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

Contemporary clinical trials communications, 2020-12, Vol.20, p.100678, Article 100678

2020

Link zum Volltext

Verfügbarkeit prüfen

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

BMC cancer, 2010-02, Vol.10 (1), p.36-36, Article 36

2010

Link zum Volltext

Verfügbarkeit prüfen

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Clinical cancer research, 2023-01, Vol.29 (2), p.389-400

2023

Link zum Volltext

Verfügbarkeit prüfen

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

Clinical cancer research, 2023-04, Vol.29 (8), p.1557-1568

2023

Link zum Volltext

Verfügbarkeit prüfen

Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

European journal of clinical nutrition, 2022-09, Vol.76 (9), p.1343-1346

2022

Link zum Volltext

Verfügbarkeit prüfen

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

European journal of cancer (1990), 2019-10, Vol.120, p.54-64

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Neoadjuvant Trials in ER + Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER + Breast Cancer

Trajectories of alcohol consumption during life and the risk of developing breast cancer

Correction: Neoadjuvant Trials in ER + Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women

Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype

Correction: ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER + Breast Cancer

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

Suchergebnisse filtern